(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.75%.
Inovio Pharmaceuticals's earnings in 2026 is -$67,427,048.On average, 5 Wall Street analysts forecast INO's earnings for 2026 to be -$95,032,659, with the lowest INO earnings forecast at -$106,396,046, and the highest INO earnings forecast at -$72,740,154. On average, 4 Wall Street analysts forecast INO's earnings for 2027 to be -$52,567,298, with the lowest INO earnings forecast at -$97,276,385, and the highest INO earnings forecast at -$26,056,175.
In 2028, INO is forecast to generate -$12,531,779 in earnings, with the lowest earnings forecast at -$12,159,548 and the highest earnings forecast at -$13,028,087.